| 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway MG LaPorte, DJ da Paz Lima, F Zhang, M Sen, JR Grandis, D Camarco, ... Bioorganic & medicinal chemistry letters 24 (21), 5081-5085, 2014 | 16 | 2014 |
| 333 Mapping Effector–Phenotype Landscapes in KRAS-Driven Cancers 335 Turning Cold Tumors Hot by Blocking TGF-β P Uhlén, N Tanaka, F Marongiu, M Serra, E Laconi, RD Chow, S Chen, ... | | |
| 4373 Defining the role of non-canonical PIK3CA mutations in head and neck squamous cell carcinoma MJE Lee, N Jin, J Cho, P Kwok-shing, GB Mills, DE Johnson, JR Grandis Journal of Clinical and Translational Science 4 (s1), 5-5, 2020 | | 2020 |
| 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity DM Huryn, P Wipf, JR Grandis, MG Laporte, PA Johnston, ME Schurdak, ... US Patent 11,111,253, 2021 | | 2021 |
| 6-Aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity DM Huryn, P Wipf, JR Grandis, MG Laporte, PA Johnston, ME Schurdak, ... US Patent 10,618,914, 2020 | 1 | 2020 |
| 8. Dental infection and its consequences B Hathaway, JR Grandis, JT Johnson Clinical Infectious Disease, 63, 2015 | | 2015 |
| A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and … RL Ferris, AP Kotsakis, DE Heron, S Kim, U Duvvuri, GJ Kubicek, ... Journal of Clinical Oncology 28 (15_suppl), TPS262-TPS262, 2010 | 4 | 2010 |
| A prognostic model of head and neck cancer ties TP53 mutation to 3p loss AM Gross, RK Orosco, JP Shen, AM Egloff, H Carter, M Hoffree, ... Cancer Research 74 (19_Supplement), 3821-3821, 2014 | 1 | 2014 |
| A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity DL Swaney, DJ Ramms, Z Wang, J Park, Y Goto, M Soucheray, N Bhola, ... Science 374 (6563), eabf2911, 2021 | 41 | 2021 |
| A safety evaluation study of STAT-3 Decoy (NSC-741763) in cynomolgus monkeys P Tosca, C Zwayer, M Ryan, K Knostman, J Johnson, P Giclas, J Grandis, ... Cancer Research 68 (9_Supplement), 2222-2222, 2008 | | 2008 |
| A sensible approach to targeting STAT3-mediated transcription NE Bhola, DE Johnson, JR Grandis Annals of Translational Medicine 4 (Suppl 1), 2016 | 3 | 2016 |
| A watershed year for improvements in treatment? AP Algazi, JR Grandis Nature reviews Clinical oncology 14 (2), 76-78, 2017 | 27 | 2017 |
| A young man with chronic discharge from the skin of the lateral neck AV Prabhu, J Grandis, BF Branstetter JAMA Otolaryngology–Head & Neck Surgery 142 (1), 99-100, 2016 | 1 | 2016 |
| Aberrant kinase signaling: lessons from head and neck cancer EG Nelson, JR Grandis Future Medicine Ltd 3 (3), 353-361, 2007 | 6 | 2007 |
| Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to Pseudomonas exotoxin transforming growth factor α-PE38 SM Thomas, Q Zeng, MW Epperly, WE Gooding, I Pastan, QC Wang, ... Clinical cancer research 10 (20), 7079-7087, 2004 | 18 | 2004 |
| Abrogation of transforming growth factor-α/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines JI Song, MN Lango, JD Hwang, SD Drenning, Q Zeng, WW Lamph, ... Cancer research 61 (15), 5919-5925, 2001 | 55 | 2001 |
| Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo F Riedel, K Götte, M Li, K Hörmann, JR Grandis International journal of oncology 23 (3), 577-583, 2003 | 44 | 2003 |
| Abstract A134: Honokiol targets STAT3 in head and neck squamous cell carcinoma R Leeman Neill, Q Cai, J Arbiser, J Grandis Cancer Prevention Research 1 (7_Supplement), A134-A134, 2008 | | 2008 |
| Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC. KP Pendleton, VW Lui, Y Lu, BR Gilbert, K Levine, GB Mills, JR Grandis Molecular Cancer Therapeutics 12 (11_Supplement), A23-A23, 2013 | | 2013 |
| Abstract A39: PI3K inhibition in preclinical models of HNSCC ML Hedberg, H Li, Y Zeng, JR Grandis Molecular Cancer Therapeutics 14 (7_Supplement), A39-A39, 2015 | | 2015 |
